Gossamer Bio, Inc. (GOSS) — Analyst outlook / Analyst consensus target is. Based on 17 analyst ratings, the consensus is bullish — 9 Buy, 6 Hold, 2 Sell.
The consensus price target is $0.77 (low: $0.30, high: $1.00), representing an upside of 78.4% from the current price $0.43.
Analysts estimate Earnings Per Share (EPS) of $-0.28 and revenue of $0.11B for the next fiscal year.
Earnings Per Share (EPS) track record: 2024: actual $-0.25 vs est $-0.28 (beat +11.5%). 2025: actual $-0.75 vs est $-0.74 (missed -1.2%). Analyst accuracy: 93%.
GOSS Stock — 12-Month Price Forecast
$0.77
▲ +78.41% Upside
Average Price Target
Based on 17 Wall Street analysts offering 12-month price targets for Gossamer Bio, Inc., the average price target is $0.77, with a high forecast of $1.00, and a low forecast of $0.30.
The average price target represents a +78.41% change from the last price of $0.43.
Highest Price Target
$1.00
Average Price Target
$0.77
Lowest Price Target
$0.30
GOSS Analyst Ratings
Buy
Based on 17 analysts giving stock ratings to Gossamer Bio, Inc. in the past 3 months
EPS Estimates — GOSS
93%
Analyst Accuracy
Accurate
2 years compared
Actual vs Estimate
2024
Actual –$0.25
vs Est –$0.28
▲ 13.0% off
2025
Actual –$0.75
vs Est –$0.74
▼ 1.1% off
Profitability Outlook
Company has been making losses in all recent fiscal years. Analysts expect losses to continue near-term.
Revenue Estimates — GOSS
92%
Analyst Accuracy
Accurate
2 years compared
Actual vs Estimate
2024
Actual $0.115B
vs Est $0.112B
▲ 2.2% off
2025
Actual $0.048B
vs Est $0.042B
▲ 12.9% off
Revenue Trend
Revenue has declined over the period shown. Analysts forecast significant revenue growth ahead.
